Skip to main content

Table 7 Risk of SPM after lung HGNEC, stratified by latency

From: Risk of second primary malignancy in adults with pulmonary high-grade neuroendocrine carcinoma (HGNEC)

  6–11 months 95% CI Excess risk 12–59 months 95% CI Excess risk 60–119 months Excess risk 120+ months Excess risk
O E O/E O E O/E O E O/E 95% CI O E O/E 95% CI
All Sites 174 236.63 0.74 0.63–0.85 −40.5 679 458.53 1.48 1.37–1.6 73.86 380 152.97 2.48 2.24–2.75 241.94 128 39.35 3.25 2.71–3.87 389.58
All Solid Tumours 162 211.36 0.77 0.65–0.89 −31.91 603 408.91 1.47 1.36–1.6 65.02 356 135.52 2.63 2.36–2.91 234.95 120 34.63 3.47 2.87–4.14 375.2
Oral Cavity and Pharynx 9 5.45 1.65 0.75–3.13 2.29 14 10.3 1.36 0.74–2.28 1.24 5 3.42 1.46 0.47–3.41 1.68 2 0.88 2.26 0.27–8.16 4.9
Digestive System 53 43.96 1.21 0.9–1.58 5.84 105 85.1 1.23 1.01–1.49 6.67 51 28.64 1.78 1.33–2.34 23.82 18 7.46 2.41 1.43–3.81 46.33
Respiratory System 34 38.64 0.88 0.61–1.23 −3 317 74.79 4.24 3.78–4.73 81.14 222 25.03 8.87 7.74–10.12 209.9 77 6.52 11.81 9.32–14.76 309.74
Breast 15 30.34 0.49 0.28–0.82 −9.92 39 64.32 0.61 0.43–0.83 −8.48 26 21.86 1.19 0.78–1.74 4.41 6 5.66 1.06 0.39–2.31 1.51
Female Genital System 2 11.64 0.17 0.02–0.62 −6.23 12 24.82 0.48 0.25–0.84 −4.29 5 8.47 0.59 0.19–1.38 −3.7 1 2.17 0.46 0.01–2.57 −5.14
Male Genital System 10 42.93 0.23 0.11–0.43 −21.29 30 74.99 0.4 0.27–0.57 −15.07 12 21.95 0.55 0.28–0.96 −10.6 7 4.97 1.41 0.57–2.9 8.9
Urinary System 28 20.22 1.39 0.92–2 5.03 62 38.71 1.6 1.23–2.05 7.8 23 13.5 1.7 1.08–2.56 10.12 4 3.6 1.11 0.3–2.85 1.76
All Lymphatic and Hematopoietic Diseases 7 19.72 0.35 0.14–0.73 −8.23 61 38.79 1.57 1.2–2.02 7.44 21 13.66 1.54 0.95–2.35 7.82 6 3.7 1.62 0.6–3.53 10.12